Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

NCT05950516 · Unknown status

Last updated 2026-05-28

This clinical trial tested the effects of semaglutide injections on people with type 2 diabetes to see how it affects their HbA1c levels.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 478 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2023-07 · est. completion 2025-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05950516 ↗

Description as written by the study sponsor.

To evaluate the similarity of the efficacy and safety of semaglutide injection (QLG2065) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.

Treatments tested

Semaglutide also known as QLG2065 Drug

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
Semaglutide Pen Injector [Ozempic] also known as Ozempic Injectable Product Drug

Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks

Main thing measured	Change in HbA1c
Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05950516 ↗